HMG-CoA Reductase Inhibitor: Primary Prevention
{"Image DocumentName": "HMG-CoA Reductase Inhibitor: Primary Prevention", "Image ImageDescription": "West of Scotland Coronary Prevention Study (WOSCOPS) 6,595 men with moderate hypercholesterolemia randomized to pravastatin (40 mg) or placebo for 5 years. Statins provide significant benefit in those with average cholesterol levels. 31% RRR Rate of MI or CHD death (%) 3. P< The West of Scotland Coronary Prevention Study (WOSCOPS) found that pravastatin significantly reduced the rate of MI or death from coronary heart disease in men with average cholesterol levels. Total coronary events, however, fell from ~10% to 7% over a 5 year period. Placebo. Pravastatin. CHD=Coronary heart disease, MI=Myocardial infarction, RRR=Relative risk reduction. Shepherd J et al. NEJM 1995;333:", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}